Repost: 2014 Estimate of Revenue from TLT NMIBC treatmentRoger Dumoulin-White wrote in the April 2014 Cantech Letter:
"Annual sales would ramp immediately after commercialization, but assuming a treatment cost of $50,000 per patient with 1000 patients treated annually at each of 50 facilities, gross revenue from the procedures would total $2.5-billion. If Theralase was paid 50% of the gross revenue for the PDC and the laser system used to activate it, the Company’s gross revenues after a two to three year ramp could potentially be $1.25-billion per year."